Clinical Trial

A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major

Name: A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major — clinical trial record (NCT07489196)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 in treating patients with β-Thalassemia Major

Trial Details

NCT Number	NCT07489196
Lead Sponsor	CorrectSequence Therapeutics Co., Ltd
Conditions	β-thalassemia Major
Enrollment	20 participants
Start Date	2026-04-05
Primary Completion	2028-01-31 (estimated)
Study Completion	2028-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-24